Cocalero Bio Secures Over RMB 10 Million in Strategic Investment from Biotsmile Pharma Group

On October 23, Kuke Nuo Biotechnology (Hangzhou) Co., Ltd. (hereinafter referred to as “Kuke Nuo Bio”) completed a strategic investment of over RMB 10 million from Shimai Pharmaceutical Group.

Coolcano Biotech is an emerging enterprise primarily engaged in biosafety monitoring. Founded in 2023, the company is an innovative technology venture jointly established by doctoral teams from Fudan University and Sichuan University, boasting a highly qualified and specialized technical and marketing team.

With continuous innovations in genetic engineering and biotechnology, the biopharmaceutical industry is experiencing rapid growth worldwide and has been regarded by nations across the globe as a critical component of strategic development. It is evident from the decisions made by leading domestic pharmaceutical companies that internationalization has become a clear direction for the development of China’s biopharmaceutical sector. However, amidst this rapid industry expansion, one cornerstone remains unshakable: a compliant quality control system and biosafety testing.

Kukenuo Biology has established independent third-party animal testing laboratories in Suzhou, Xi’an, Taiyuan, and Kunming. Meanwhile, it has jointly built an “industry-academia-research” platform for laboratory animals with multiple renowned universities and research institutes across China, providing customized services nationwide. Through this partnership with Shimai Pharmaceutical Group, the company is committed to improving the quality of laboratory animals in China, offering high-quality, end-to-end animal experimentation services to researchers, and thereby advancing biomedical research.

Shimai Pharmaceutical Group, guided by its mission to “drive the pharmaceutical industry and empower pharmaceutical dreams,” has been deeply engaged in the sector for 13 years. Leveraging China’s largest talent data platform for the life and health industry (covering 5.86 million individuals) and extensive resources across the upstream and downstream industrial chain (involving 101,300 enterprises), the group centers its operations on the Biotsmile One-Stop Service Platform for the Intelligent Digital Pharmaceutical Industrial Chain. It provides a comprehensive suite of services, including talent and intelligence acquisition, industrial park development and operation, investment promotion along the industrial chain, industrial planning, professional training, startup incubation, investment and financing, and conferences and forums.With subsidiaries established in Hangzhou, Shanghai, Beijing, Wuhan, Zhengzhou, Nanjing, Suzhou, Guangzhou, Chengdu, Taiyuan, Nanchang, Qingdao, and Shenzhen, as well as cooperation hubs in Europe, the United States, and India for introducing elite talent and innovative projects, Shimai has constructed a distinctive ecosystem service chain for the biopharmaceutical industry. The recent partnership with KukeNuo Biology represents strong support and deep empowerment for outstanding entrepreneurial teams in the biopharmaceutical sector. This collaboration further enhances Shimai’s intelligent digital pharmaceutical industry service chain, accelerates innovation and entrepreneurship in biopharma, promotes regional industrial clustering, reduces industry costs, and improves overall industrial efficiency.